Last reviewed · How we verify
NCT07376499
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
Phase 2 trial testing Liposome Irinotecan in Small Cell Lung Cancer in 31 participants. Not yet recruiting.
31 March 2026
Quick facts
| Lead sponsor | China Medical University, China |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 31 |
| Start date | 25 January 2026 |
| Primary completion | 31 March 2026 |
| Estimated completion | 30 June 2027 |
Drugs / interventions tested
- Liposome Irinotecan — full drug profile →
- Platinum (PLATINUM) — full drug profile →
- Anlotinib — full drug profile →
- Toripalimab (TORIPALIMAB) — full drug profile →
Conditions studied
- Small Cell Lung Cancer — all drugs for Small Cell Lung Cancer →
Sponsor
China Medical University, China
Who can join
18 and older, any sex, with Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the efficacy and safety of liposome irinotecan combined with platinum and immune checkpoint inhibitor combined with antirotinib maintenance therapy after first-line induction
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07376499
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Liposome Irinotecan
Trials testing the same drug.
- NCT06951841 — Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum a · Phase 4 · not yet recruiting
Other recruiting trials for Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
- NCT07296809 — SKB500 Combinations in Patients With Small Cell Lung Cancer · Phase 2 · recruiting
- NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
- NCT06922539 — ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer · Phase 1 · recruiting
- NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting
Other China Medical University, China trials
Trials by the same sponsor.
- NCT07519837 — Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics · NA · recruiting
- NCT07388875 — Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC · Phase 2 · not yet recruiting
- NCT07262840 — Health Behavior Change in High-Risk Colorectal Cancer Individuals · NA · recruiting
- NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting
- NCT07034391 — A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metast · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07376499 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by China Medical University, China
- Last refreshed: 29 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07376499.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing